The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not ...

Jesy Nelson's twin daughters have been fitted with leg splints to "flatten out" their feet. The former Little Mix singer ...

Jesy Nelson's twin daughters Ocean Jade and Story Monroe have been diagnosed with spinal muscular atrophy (SMA) ...

But for Brooklyn, who lives with spinal muscular atrophy, or SMA, a rare genetic condition that affects muscle strength and ...

Genetic switches near the FTO locus may enable hibernators’ extreme metabolic resilience and could inspire future treatments ...

Discover the hidden complication of muscle loss among CKD patients, as highlighted by a recent study. Learn how sarcopenia affects nearly 25% of CKD patients in Asia, with significant implications for ...

First-in-class oral therapy mimics the effects of exercise with broad potential as a novel treatment for muscle-sparing weight loss ...

First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential as a novel treatment for muscle-sparing weight ...

While life-long oral treatment is subsidised by the government, one-off gene therapies are not. Read more at straitstimes.com ...

AN EXERCISE pill that mimics a workout to build muscle and burn fat has entered human patient trials for the first time. A ...

The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was hobbled by manufacturing concerns at a Novo Nordisk facility last year but ...